AllSight
ALMR · LABORATORY ANALYTICAL INSTRUMENTS · 8-K · Item 2.02 · Aug 10, 2026

Revenue surged, but heavier spending keeps the read firmly mixed

Alamar Biosciences, Inc. (ALMR) — AllSight decodes this SEC 8-K in plain English, versus what the market expected.

There is no clean published Q2 revenue benchmark to call a beat or miss. Available public estimate pages identify analyst coverage but do not provide a usable Q2 revenue consensus in the accessible results, while the company had not issued full-year 2026 guidance as of its May 8 report. The appropriate anchor is therefore the prior quarter's $26.0 million revenue and the market's broad expectation for continued rapid post-IPO growth—not the company's promotional wording.

The top line continued to outperform its own recent pace. Q2 revenue reached $29.4 million, up 82% year over year and roughly 13% above Q1's $26.0 million. Consumables were the clear engine at $15.5 million, up 147%, while instruments grew 35% to $7.8 million and services rose 49% to $6.2 million (Revenue by source). That mix matters because consumables carry better economics and support a recurring pull-through model.

MetricQ2 2026Q2 2025Change / context
Total revenue$29.4M$16.2M+82% (Income Statement)
Instruments$7.8M$5.8M+35% (Revenue by source)
Consumables$15.5M$6.3M+147% (Revenue by source)
Services$6.2M$4.1M+49% (Revenue by source)
Gross margin60%53%+7 percentage points (Financial Results)
Operating expenses$31.3M$16.5M+89% (Income Statement)
Operating loss$(13.5)M$(7.9)MLoss widened (Income Statement)
Net loss$(13.2)M$(7.0)MLoss widened (Income Statement)
Cash, investments and restricted cash$256.3MAs of June 30, 2026 (Balance Sheets / Financial Results)

The profitability improvement is real at the gross-profit level, but not yet reaching the bottom line. Gross margin expanded to 60% from 53% as consumables became a larger share of sales and manufacturing efficiency improved (Financial Results). However, operating expenses rose 89%, faster than revenue, driven by hiring, infrastructure, R&D and public-company costs; operating loss consequently widened to $13.5 million (Income Statement). Stock-based compensation also increased to $3.3 million from $0.7 million (Stock-based compensation table), so the quarter shows operating leverage potential rather than delivered operating leverage.

The new guidance is constructive but not a clear upside reset. Full-year revenue guidance of $116 million to $120 million implies a $118 million midpoint and 59% growth over 2025 (2026 Guidance). With $55.5 million recorded in the first half (Income Statement), the company needs $60.5 million to $64.5 million in the second half—roughly $30.3 million to $32.3 million per quarter—to reach the range. That requires continued sequential growth, but the filing does not say the range was raised from an earlier forecast; it is the first formal full-year guide, so its signal is more about establishing a credible growth path than delivering a measurable guidance beat.

Net read: strong demand, better mix, but still an investment story rather than an earnings story. The revenue trajectory and consumables acceleration are better than a merely steady-growth outcome, and the $256.3 million liquidity position materially supports continued investment (Balance Sheets). But without a substantiated consensus comparison—and with operating losses widening—the filing earns a mixed read: commercially strong, financially still dependent on future scale to convert growth into earnings.

Read the original 8-K on SEC EDGAR ↗
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.